Ariad’s Iclusig Clinical Program Held Up By Mounting Cardio Events
This article was originally published in The Pink Sheet Daily
FDA issued a partial clinical hold due to the growing number of cardiovascular events in the pivotal PACE trial, which had been ongoing after ponatinib won accelerated approval based on response rate in December 2012.
You may also be interested in...
Ponatinib received accelerated approval for use in chronic myeloid leukemia and acute lymphoblastic leukemia patients who are resistant or intolerant to prior therapy with tyrosine kinase inhibitors.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.